HK1025104A1 - Gnrh antagonists being modified in positions 5 and6 - Google Patents

Gnrh antagonists being modified in positions 5 and6

Info

Publication number
HK1025104A1
HK1025104A1 HK00104333A HK00104333A HK1025104A1 HK 1025104 A1 HK1025104 A1 HK 1025104A1 HK 00104333 A HK00104333 A HK 00104333A HK 00104333 A HK00104333 A HK 00104333A HK 1025104 A1 HK1025104 A1 HK 1025104A1
Authority
HK
Hong Kong
Prior art keywords
and6
modified
positions
gnrh antagonists
gnrh
Prior art date
Application number
HK00104333A
Other languages
English (en)
Inventor
Graeme Semple
Guangcheng Jiang
Jean E F Rivier
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1025104(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HK1025104A1 publication Critical patent/HK1025104A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK00104333A 1997-04-11 2000-07-13 Gnrh antagonists being modified in positions 5 and6 HK1025104A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists
PCT/US1998/007438 WO1998046634A1 (en) 1997-04-11 1998-04-13 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6

Publications (1)

Publication Number Publication Date
HK1025104A1 true HK1025104A1 (en) 2000-11-03

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00104333A HK1025104A1 (en) 1997-04-11 2000-07-13 Gnrh antagonists being modified in positions 5 and6

Country Status (37)

Country Link
US (2) US5925730A (no)
EP (1) EP1003774B1 (no)
JP (2) JP4249806B2 (no)
KR (1) KR100519421B1 (no)
CN (1) CN1230442C (no)
AR (1) AR011217A1 (no)
AT (1) ATE319736T1 (no)
AU (1) AU728642B2 (no)
BR (1) BR9808523B1 (no)
CA (1) CA2286190C (no)
CY (2) CY1108063T1 (no)
CZ (1) CZ299097B6 (no)
DE (2) DE69833751T2 (no)
DK (1) DK1003774T3 (no)
EE (1) EE03974B1 (no)
ES (1) ES2260833T3 (no)
FR (1) FR09C0028I2 (no)
HK (1) HK1025104A1 (no)
HR (1) HRP980197B1 (no)
HU (1) HU224836B1 (no)
IL (1) IL132303A0 (no)
LU (1) LU91585I2 (no)
MY (1) MY114811A (no)
NL (1) NL300395I2 (no)
NO (2) NO324991B1 (no)
NZ (1) NZ500142A (no)
PL (1) PL194509B1 (no)
PT (1) PT1003774E (no)
RU (1) RU2199549C2 (no)
SI (1) SI1003774T1 (no)
SK (1) SK285381B6 (no)
TR (1) TR199902956T2 (no)
TW (1) TW505658B (no)
UA (1) UA58547C2 (no)
UY (1) UY24958A1 (no)
WO (1) WO1998046634A1 (no)
ZA (1) ZA983062B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
WO1999026964A1 (en) * 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
EP2322194A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
TWI539959B (zh) * 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
CN102046192B (zh) * 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
WO2010099255A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
US8828938B2 (en) * 2009-04-24 2014-09-09 Polypeptide Laboratories A/S Method for the manufacture of degarelix
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
ES2617336T3 (es) 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
JP6100699B2 (ja) 2010-12-22 2017-03-22 ザ ソルク インスティテュート フォー バイオロジカル スタディーズ 環状ｃｒｆアンタゴニストペプチド及びその薬学的に許容される塩
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
SG11201407679PA (en) 2012-06-01 2014-12-30 Ferring Bv Manufacture of degarelix
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
US11168114B2 (en) 2015-12-17 2021-11-09 Fresenius Kabi iPSUM S.r.l Process for the manufacture of degarelix and its intermediates
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP4004001A4 (en) 2019-07-29 2023-08-30 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED PYRIMIDINEONE COMPOUNDS AND USES THEREOF
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
WO2023072284A1 (zh) 2021-11-01 2023-05-04 山东绿叶制药有限公司 促性腺素释放激素拮抗剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE69214818T2 (de) * 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
WO1994014841A1 (en) * 1992-12-18 1994-07-07 Abbott Laboratories Lhrh antagonists having modified aminoacyl residues at postions 5 and 6
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
JP4249806B2 (ja) 2009-04-08
JP3645255B1 (ja) 2005-05-11
UA58547C2 (uk) 2003-08-15
BR9808523A (pt) 2000-05-23
NZ500142A (en) 2001-10-26
US6214798B1 (en) 2001-04-10
EE9900479A (et) 2000-06-15
CZ358699A3 (cs) 2000-06-14
NO994906L (no) 1999-12-13
PT1003774E (pt) 2006-05-31
EP1003774B1 (en) 2006-03-08
TR199902956T2 (xx) 2000-08-21
CN1230442C (zh) 2005-12-07
NO2009016I1 (no) 2009-08-10
UY24958A1 (es) 2001-03-16
HRP980197B1 (en) 2002-08-31
CY1108063T1 (el) 2012-01-25
SI1003774T1 (sl) 2006-08-31
HUP0002704A3 (en) 2003-08-28
SK139699A3 (en) 2000-11-07
CA2286190C (en) 2007-01-09
DE122009000033I2 (de) 2011-07-21
CY2009008I2 (el) 2012-01-25
NO2009016I2 (no) 2014-08-25
NO324991B1 (no) 2008-01-14
KR100519421B1 (ko) 2005-10-06
FR09C0028I2 (fr) 2010-06-11
ATE319736T1 (de) 2006-03-15
PL336213A1 (en) 2000-06-05
EE03974B1 (et) 2003-02-17
ES2260833T3 (es) 2006-11-01
DE69833751T2 (de) 2006-11-09
ZA983062B (en) 1998-10-20
SK285381B6 (sk) 2006-12-07
HRP980197A2 (en) 1999-02-28
NO994906D0 (no) 1999-10-08
IL132303A0 (en) 2001-03-19
CA2286190A1 (en) 1998-10-22
PL194509B1 (pl) 2007-06-29
FR09C0028I1 (no) 2009-09-25
TW505658B (en) 2002-10-11
DK1003774T3 (da) 2006-07-03
JP2001523229A (ja) 2001-11-20
EP1003774A1 (en) 2000-05-31
HUP0002704A2 (hu) 2000-12-28
RU2199549C2 (ru) 2003-02-27
CN1259959A (zh) 2000-07-12
AU728642B2 (en) 2001-01-11
KR20010006233A (ko) 2001-01-26
CY2009008I1 (el) 2012-01-25
AU6969898A (en) 1998-11-11
LU91585I2 (fr) 2009-09-17
DE122009000033I1 (de) 2009-09-17
NL300395I1 (nl) 2009-09-01
BR9808523B1 (pt) 2010-02-09
CZ299097B6 (cs) 2008-04-23
AR011217A1 (es) 2000-08-02
MY114811A (en) 2003-01-31
NL300395I2 (nl) 2010-01-04
DE69833751D1 (de) 2006-05-04
JP2005120101A (ja) 2005-05-12
HU224836B1 (en) 2006-03-28
WO1998046634A1 (en) 1998-10-22
US5925730A (en) 1999-07-20

Similar Documents

Publication Publication Date Title
HK1025104A1 (en) Gnrh antagonists being modified in positions 5 and6
DE69834346D1 (en) Proteinexpression in baculovirus-vektor expressionsystemen
HU9602550D0 (en) Gnrh antagonists
HUP0102535A3 (en) Cd19xcd3 specific polypeptides and uses thereof
DE69927412D1 (en) Phosphitadditive in polyolefinen
IL128409A0 (en) Muscarinic antagonists
EP0934305A4 (en) INTEGRINE ANTAGONISTS
PT1090128E (pt) Polipéptidos dependentes da vitamina k modificados
EP0981656A4 (en) LOW RESISTIVITY TUNGSTEN USING B 2? H 6?
GB2320435B (en) Improvements in Magnotherapy
DE69732623D1 (en) Analogsignalmultiplexer in strombetriebsart
HU9503191D0 (en) Adhesion-receptor antagonists
ZA98256B (en) Tachykinin antagonists
GB9820014D0 (en) Receptor antagonists and uses thereof
GB9701374D0 (en) Purinergic agonists and antagonists
HUP9800023A3 (en) Tee bolt
GB2330370B (en) Improvements in piling arrangements
IL129443A0 (en) Improvements in fastenings
GB9802808D0 (en) Improvements in roofing
GB9703015D0 (en) Alpha v B3 antagonists
GB9706732D0 (en) Improvements in shapemeters
GB9725996D0 (en) Intergrin antagonists
GB9719843D0 (en) Intergrin antagonists
PL106007U1 (en) Rocking-toy in particular rocking-horse
GB9610996D0 (en) µv›3 Antagonists

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180412